Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

BACKGROUND: As use of oral cancer therapies increases, patient adherence has become critical when evaluating the effectiveness of therapy. In a phase III trial for renal cell carcinoma, we: (a) characterized adherence to sorafenib, sunitinib, and/or placebo and (b) identified factors associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Caitlin C., Fullington, Hannah M., Gerber, David E., Bowman, Isaac Alex, Puligandla, Maneka, Dutcher, Janice P., DiPaola, Robert S., Haas, Naomi B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419781/
https://www.ncbi.nlm.nih.gov/pubmed/34405965
http://dx.doi.org/10.1002/cam4.4140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419781/
https://www.ncbi.nlm.nih.gov/pubmed/34405965
http://dx.doi.org/10.1002/cam4.4140

Ejemplares similares